Moshkevich's non-discretionary sale was executed to cover tax withholding on vesting RSUs under a Ru

This sale was executed under a pre-arranged Rule 10b5-1 trading plan.

This sale was non-discretionary and executed under a Rule 10b5-1 plan to cover tax withholding from

Druckenmiller only owns one "Magnificent Seven" stock.

40.6%. That is how much Natera shares have grown since the start of the year, when they were priced

TD Cowen analyst Dan Brennan maintains Natera (NASDAQ:NTRA) with a Buy and raises the price targe

Citigroup analyst Brendan Digan maintains Natera (NASDAQ:NTRA) with a Buy and raises the price ta

RBC Capital analyst Dan Leonard maintains Natera (NASDAQ:NTRA) with a Outperform and raises the p

U.S. stocks rose, Nasdaq Composite up 1%. Natera Inc (NTRA) shares jump 20.5% after strong Q2 result

Natera stock spikes as strong oncology demand drives record test volumes and a full-year revenue out

JP Morgan analyst Casey Woodring maintains Natera (NASDAQ:NTRA) with a Overweight and raises the

Wells Fargo analyst Evan Stampler maintains Natera (NASDAQ:NTRA) with a Equal-Weight and raises t

Evercore ISI Group analyst Daniel Markowitz maintains Natera (NASDAQ:NTRA) with a Outperform and

Gainers Doximity (NYSE:DOCS) stock rose 85.1% to $38.25 during Friday's pre-market session. The

BTIG analyst Mark Massaro maintains Natera (NASDAQ:NTRA) with a Buy and raises the price target f

Natera NASDAQ: NTRA reported second-quarter 2026 revenue of approximately $753 million, up about 38%

Natera (NTRA) came out with a quarterly loss of $0.47 per share in line with the Zacks Consensus Est

Natera, Inc. (NTRA) Q2 2026 Earnings Call Transcript

Gainers Doximity (NYSE:DOCS) stock increased by 65.6% to $34.22 during Thursday's after-market

Natera (NASDAQ:NTRA) raises FY2026 sales outlook from $2.740 billion-$2.820 billion to $2.850 billio

Natera (NASDAQ:NTRA) reported quarterly losses of $(0.47) per share which beat the analyst consensus

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and ge

Natera (NASDAQ:NTRA) has outperformed the market over the past 10 years by 24.85% on an annualized b

The submission advances Natera’s growing presence in Japan, where Signatera received PMDA approval i

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and pr

Cetera Investment Advisers lessened its position in shares of Natera, Inc. (NASDAQ: NTRA) by 9.5% in

The company has made massive strides in medical diagnostics and is growing at a rapid clip.

Beaconlight Capital LLC increased its holdings in shares of Natera, Inc. (NASDAQ: NTRA) by 44.2% in

Arrowstreet Capital Limited Partnership raised its position in Natera, Inc. (NASDAQ: NTRA) by 1.0% d

The study evaluated the Signatera test against the Merkel cell polyomavirus antibody test (AMERK), f

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and pr

California Public Employees Retirement System lessened its stake in shares of Natera, Inc. (NASDAQ:

Fifth Third Bancorp boosted its holdings in shares of Natera, Inc. (NASDAQ: NTRA) by 3,373.1% during

Tempus AI acquires Personalis for $1.5B to target the $20B MRD cancer monitoring market. Get full de

Amova Asset Management Americas Inc. reduced its position in Natera, Inc. (NASDAQ: NTRA) by 10.1% in

Stanley Druckenmiller doesn't do consensus. The Duquesne Family Office's latest 13F reveals a top-fi

Allspring Global Investments Holdings LLC grew its holdings in Natera, Inc. (NASDAQ: NTRA) by 2.0% d

Canaccord Genuity analyst Kyle Mikson maintains Natera (NASDAQ:NTRA) with a Buy and raises the pr

Eledon has established the regulatory framework for its Phase 3 kidney transplantation program and p

Tom Lee's GRNJ added First Solar, Zoom and eight other stocks in its latest rebalance as assets

Discover last week's top 10 large-cap stock gainers, why they rallied, and what catalysts drove

Elevance Health and Waters led the weekly large-cap losers, hit by weak earnings, lowered guidance,

Billionaire Stanley Druckenmiller's latest large wager on biotech company Natera Inc has paid of